A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Incidence of Hypersensitivity After Repeated Single Dose Administration of Sugammadex (MK-8616) in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 07 Oct 2015
At a glance
- Drugs Sugammadex (Primary)
- Indications Neuromuscular blockade
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 15 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Mar 2014 Status changed from recruiting to active, no longer recruiting according to ClinicalTrials.gov record.
- 13 Jan 2014 New trial record